Primary Site >> Colorectal Cancer
Gene >> MAP2K1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. PMID: 9191056 |
Ref: Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras. PMID: 9926923 Ref: Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells. PMID: 10344756 |
Ref: Erk1/2-dependent phosphorylation of Galpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. PMID: 10993892 Ref: Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades. PMID: 11085935 |
Ref: Alternative activation of extracellular signal-regulated protein kinases in curcumin and arsenite-induced HSP70 gene expression in human colorectal carcinoma cells. PMID: 11322385 Ref: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. PMID: 11781819 |
Ref: The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. PMID: 11992399 |
Ref: Opposing effects of butyrate and bile acids on apoptosis of human colon adenoma cells: differential activation of PKC and MAP kinases. PMID: 12618885 Ref: Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. PMID: 14556662 Ref: Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. PMID: 14625389 |
Ref: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. PMID: 14695993 Ref: Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. PMID: 14750214 Ref: Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. PMID: 15078890 Ref: Expression patterns of cell cycle and apoptosis-related genes in a multidrug-resistant human colon carcinoma cell line. PMID: 15180185 Ref: Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. PMID: 15210862 Ref: Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. PMID: 15247276 Ref: Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. PMID: 15294323 Ref: Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. PMID: 15322124 Ref: Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. PMID: 15548677 |
Ref: Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. PMID: 15655297 Ref: Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. PMID: 15657353 Ref: Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation. PMID: 15735687 Ref: Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyri din-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxami PMID: 15901852 Ref: Molecular mechanisms of denbinobin-induced anti-tumorigenesis effect in colon cancer cells. PMID: 15918186 Ref: A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. PMID: 15967111 Ref: Transcriptional regulation of activating transcription factor 3 involves the early growth response-1 gene. PMID: 16079301 Ref: Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. PMID: 16083714 |
Ref: Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. PMID: 16278684 Ref: Radiation-induced upregulation of gamma-glutamyltransferase in colon carcinoma cells is mediated through the Ras signal transduction pathway. PMID: 16386375 Ref: RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. PMID: 16505104 Ref: Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. PMID: 16574647 Ref: Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. PMID: 16575407 Ref: The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. PMID: 16595125 Ref: Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells. PMID: 16984735 Ref: Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. PMID: 17112382 |
Ref: XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer. PMID: 17385215 Ref: Signal-dependent control of autophagy and cell death in colorectal cancer cell: the role of the p38 pathway. PMID: 17495519 Ref: Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. PMID: 17631144 Ref: Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. PMID: 17667937 Ref: Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor. PMID: 17784872 Ref: 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. PMID: 17880056 |
Ref: Suppression of v-Src transformation by andrographolide via degradation of the v-Src protein and attenuation of the Erk signaling pathway. PMID: 18086662 Ref: Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). PMID: 18186519 Ref: Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. PMID: 18507034 Ref: Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells. PMID: 18533112 Ref: Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. PMID: 18676857 Ref: Inhibition of growth and induction of differentiation of colon cancer cells by peach and plum phenolic compounds. PMID: 18751377 Ref: Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3. PMID: 18771677 Ref: Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. PMID: 18790789 Ref: Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. PMID: 18806830 Ref: Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. PMID: 19014680 |
Ref: Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyraz ol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated PMID: 19147858 Ref: Netrin-1 increases proliferation and migration of renal proximal tubular epithelial cells via the UNC5B receptor. PMID: 19211685 Ref: MAP kinases in proliferating human colon cancer Caco-2 cells. PMID: 19301097 Ref: Role of eotaxin-1 signaling in ovarian cancer. PMID: 19351767 Ref: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. PMID: 19372556 Ref: MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. PMID: 19411838 Ref: Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway. PMID: 19472191 Ref: Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PMID: 19492075 Ref: Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. PMID: 19637312 Ref: The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. PMID: 19843666 |
Ref: Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. PMID: 19782465 Ref: Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models. PMID: 20053779 Ref: Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway. PMID: 20198339 Ref: Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition. PMID: 20413844 Ref: Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. PMID: 20725992 Ref: Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. PMID: 20923857 Ref: The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. PMID: 20942929 |
Ref: A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. PMID: 20127139 Ref: Esculetin inhibits cell proliferation through the Ras/ERK1/2 pathway in human colon cancer cells. PMID: 21109980 Ref: MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. PMID: 21118963 Ref: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. PMID: 21148749 Ref: Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin. PMID: 21169384 Ref: Activation and involvement of Ral GTPases in colorectal cancer. PMID: 21199803 Ref: Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. PMID: 21317303 Ref: Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. PMID: 21447798 Ref: Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. PMID: 21523318 Ref: A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P PMID: 21674991 Ref: Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. PMID: 21705440 Ref: An RNA interference phenotypic screen identifies a role for FGF signals in colon cancer progression. PMID: 21853123 Ref: Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. PMID: 21923915 Ref: Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. PMID: 22045189 |
Ref: Tissue factor/activated factor VIIa induces matrix metalloproteinase-7 expression through activation of c-Fos via ERK1/2 and p38 MAPK signaling pathways in human colon cancer cell. PMID: 22076613 Ref: Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. PMID: 22169769 Ref: Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. PMID: 22260668 Ref: Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. PMID: 22298595 Ref: Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. PMID: 22361730 Ref: Ras signaling pathway in the chemopreventive action of different ratios of fish oil and corn oil in experimentally induced colon carcinogenesis. PMID: 22519408 Ref: Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. PMID: 22569000 Ref: Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. PMID: 22579651 Ref: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. PMID: 22773810 Ref: MAP kinase genes and colon and rectal cancer. PMID: 23027623 Ref: Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometry. PMID: 23304816 Ref: (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. PMID: 23372439 |
Ref: Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. PMID: 22948716 Ref: The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. PMID: 23234544 Ref: Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. PMID: 23319808 Ref: MAT2B-GIT1 interplay activates MEK1/ERK 1 and 2 to induce growth in human liver and colon cancer. PMID: 23325601 Ref: Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. PMID: 23445752 Ref: Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. PMID: 23757356 Ref: Trametinib: first global approval. PMID: 23846731 Ref: Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. PMID: 23942066 Ref: Multi-kinase modulation for colon cancer therapy. PMID: 24025253 Ref: Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. PMID: 24045180 Ref: BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. PMID: 24190114 |
Ref: Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. PMID: 24363449 Ref: Paris saponin VII inhibits growth of colorectal cancer cells through Ras signaling pathway. PMID: 24462916 Ref: Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. PMID: 24553387 Ref: The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. PMID: 24700299 Ref: Trametinib. PMID: 24756797 Ref: EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules. PMID: 24792576 Ref: Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. PMID: 24812410 Ref: Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. PMID: 24885690 Ref: Disruption of interleukin-1beta autocrine signaling rescues complex I activity and improves ROS levels in immortalized epithelial cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function. PMID: 24901709 Ref: Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines. PMID: 25309914 Ref: Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. PMID: 25379021 Ref: The effect of resveratrol on signal transduction pathways and the role of pro-apoptotic Bax protein on apoptosis in HCT- 116 colon carcinoma cell lines. PMID: 26461322 |
Ref: Netrin-1 improves post-injury cardiac function in vivo via DCC/NO-dependent preservation of mitochondrial integrity, while attenuating autophagy. PMID: 24928309 Ref: Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. PMID: 25326806 Ref: Oncogenic KRAS signalling promotes the Wnt/beta-catenin pathway through LRP6 in colorectal cancer. PMID: 25500543 Ref: Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. PMID: 25673644 Ref: Novel molecular insights from routine genotyping of colorectal carcinomas. PMID: 25683705 Ref: Methionine adenosyltransferase 2B-GIT1 complex serves as a scaffold to regulate Ras/Raf/MEK1/2 activity in human liver and colon cancer cells. PMID: 25794709 Ref: HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. PMID: 25813020 Ref: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. PMID: 26030179 Ref: Screening of potential diagnostic markers and therapeutic targets against colorectal cancer. PMID: 26185457 Ref: The genomic landscape of response to EGFR blockade in colorectal cancer. PMID: 26416732 |
Ref: The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model. PMID: 26276154 Ref: Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. PMID: 26644315 Ref: Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. PMID: 26660078 Ref: A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. PMID: 26666244 Ref: Nanoproteomic analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissue. PMID: 26742633 Ref: Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. PMID: 26797410 Ref: Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. PMID: 26959608 Ref: Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1. PMID: 26979829 Ref: [Alpha-1 Antitrypsin Affects U0126-Induced Cytotoxicity in Colon Cancer Cell Line (HCT116)]. PMID: 27028823 Ref: The ERK1/2 and mTORC1 Signaling Pathways Are Involved in the Muscarinic Acetylcholine Receptor-Mediated Proliferation of SNU-407 Colon Cancer Cells. PMID: 27167250 Ref: ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation. PMID: 27187615 Ref: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. PMID: 27259276 Ref: Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. PMID: 27312529 Ref: Autophagy regulates Selumetinib (AZD6244) induced-apoptosis in colorectal cancer cells. PMID: 27448918 Ref: Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer. PMID: 27472952 Ref: Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing. PMID: 27568332 Ref: Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. PMID: 27682134 Ref: Muscarinic acetylcholine receptors mediate eIF4B phosphorylation in SNU-407 colon cancer cells. PMID: 27773818 Ref: PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK. PMID: 27806324 Ref: Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells. PMID: 27842582 Ref: [A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy]. PMID: 28133136 |
Ref: Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib. PMID: 27321184 Ref: Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies. PMID: 27399333 Ref: A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. PMID: 27650277 Ref: Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. PMID: 27663511 Ref: Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. PMID: 27811010 Ref: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. PMID: 28152546 Ref: A food-based approach that targets interleukin-6, a key regulator of chronic intestinal inflammation and colon carcinogenesis. PMID: 28193578 Ref: Glucose-derived AGEs promote migration and invasion of colorectal cancer by up-regulating Sp1 expression. PMID: 28237576 Ref: The anti-metastatic effect of baicalein on colorectal cancer. PMID: 28259937 Ref: HMG-CoA synthase 1 is a synthetic lethal partner of BRAF(V600E) in human cancers. PMID: 28468827 Ref: MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. PMID: 28551618 Ref: Genomic Profiling of Small-Bowel Adenocarcinoma. PMID: 28617917 Ref: BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity. PMID: 28655712 Ref: Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells. PMID: 28756770 Ref: MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. PMID: 28819429 Ref: Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. PMID: 28931905 Ref: EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features. PMID: 28936923 Ref: Pharmacoproteomic characterisation of human colon and rectal cancer. PMID: 29101300 Ref: Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. PMID: 29137301 |
Ref: LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity. PMID: 29149105 Ref: Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells. PMID: 29255136 Ref: Racial Disparities in the Molecular Landscape of Cancer. PMID: 29599344 Ref: Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. PMID: 29755687 Ref: AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells. PMID: 29846015 Ref: The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids. PMID: 29915160 Ref: Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. PMID: 30103709 Ref: Design, Synthesis and Biological Activity Evaluation of S-Substituted 1H-5-Mercapto-1,2,4-Triazole Derivatives as Antiproliferative Agents in Colorectal Cancer. PMID: 30234098 Ref: Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance. PMID: 30275173 |